Home
BIVI
BIVI News

Latest BioVie Inc. (BIVI) News on February 23, 2025

Is BioVie (NASDAQ:BIVI) In A Good Position To Invest In Growth?

Simply Wall St.

10 days ago

Is BioVie (NASDAQ:BIVI) In A Good Position To Invest In Growth?

ACCESS Newswire

a month ago

BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

GlobeNewswire

3 months ago

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded

GlobeNewswire

4 months ago

BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded

BioVie Inc. Announces Closing of Registered Direct Offering

GlobeNewswire

4 months ago

BioVie Inc. Announces Closing of Registered Direct Offering

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

4 months ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

4 months ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

4 months ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

MT Newswires

4 months ago

Top Premarket Gainers

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

4 months ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Announces Stock Offering and Private Placement

TipRanks

4 months ago

BioVie Announces Stock Offering and Private Placement

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

GlobeNewswire

4 months ago

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

4 months ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

MT Newswires

4 months ago

BioVie Shares Surge After Pricing $6.6 Million Direct Offering, Private Placement of Warrants

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

4 months ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

GlobeNewswire

4 months ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

4 months ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

GlobeNewswire

5 months ago

BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. Announces Closing of Public Offering

GlobeNewswire

5 months ago

BioVie Inc. Announces Closing of Public Offering

MT Newswires

5 months ago

Top Midday Decliners

MT Newswires

5 months ago

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday

MT Newswires

5 months ago

Sector Update: Health Care

MT Newswires

5 months ago

BioVie Prices Offering of 1.96 Million Shares, Warrants; Stock Drops Premarket

BioVie Inc. Announces Pricing of Public Offering

GlobeNewswire

5 months ago

BioVie Inc. Announces Pricing of Public Offering

MT Newswires

5 months ago

BioVie Plans Public Offering; Stock Drops After-Hours

BioVie Inc. Announces Proposed Public Offering

GlobeNewswire

5 months ago

BioVie Inc. Announces Proposed Public Offering

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

GlobeNewswire

5 months ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

MT Newswires

6 months ago

BioVie Secures FDA Authorization for Phase 2 Study on Long COVID Treatment

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

GlobeNewswire

6 months ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

GlobeNewswire

6 months ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

GlobeNewswire

6 months ago

BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease

GlobeNewswire

6 months ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease

BioVie Inc. Announces Reverse Stock Split

GlobeNewswire

7 months ago

BioVie Inc. Announces Reverse Stock Split

Individual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap decline

Simply Wall St.

7 months ago

Individual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap decline

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

8 months ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

GlobeNewswire

8 months ago

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

8 months ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

GlobeNewswire

8 months ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26

GlobeNewswire

8 months ago

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

GlobeNewswire

9 months ago

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

GlobeNewswire

9 months ago

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

MT Newswires

10 months ago

BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

GlobeNewswire

10 months ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

GlobeNewswire

10 months ago

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

GlobeNewswire

10 months ago

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

10 months ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now

Zacks

a year ago

Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

GlobeNewswire

a year ago

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

BioVie Inc. Announces Closing of Public Offering

GlobeNewswire

a year ago

BioVie Inc. Announces Closing of Public Offering

BioVie Inc. Announces Pricing of Public Offering

GlobeNewswire

a year ago

BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire

a year ago

BioVie Inc. Announces Proposed Public Offering of Common Stock

BioVie Inc. Announces Proposed Public Offering of Common Stoc

GlobeNewswire

a year ago

BioVie Inc. Announces Proposed Public Offering of Common Stoc

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

GlobeNewswire

a year ago

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire

a year ago

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

Business Wire

a year ago

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

18 Best 52-Week Low Stocks To Buy Now

Insider Monkey

a year ago

18 Best 52-Week Low Stocks To Buy Now

SurgePays Announces Strategic Partnership with SIN PIN

GlobeNewswire

a year ago

SurgePays Announces Strategic Partnership with SIN PIN

Provident Financial Holdings To Host Earnings Release Conference Call

GlobeNewswire

a year ago

Provident Financial Holdings To Host Earnings Release Conference Call

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

GlobeNewswire

a year ago

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

GlobeNewswire

a year ago

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

a year ago

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Business Wire

a year ago

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership

Business Wire

a year ago

Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership

CMCT Declares Preferred Stock Dividends

Business Wire

a year ago

CMCT Declares Preferred Stock Dividends

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

a year ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

a year ago

Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

/C O R R E C T I O N -- Cadiz, Inc./

PR Newswire

a year ago

/C O R R E C T I O N -- Cadiz, Inc./

Optimism for Eastern (NASDAQ:EML) has grown this past week, despite one-year decline in earnings

Simply Wall St.

a year ago

Optimism for Eastern (NASDAQ:EML) has grown this past week, despite one-year decline in earnings

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

a year ago

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Independent Bank Group (IBTX) Surges 8.7%: Is This an Indication of Further Gains?

Zacks

a year ago

Independent Bank Group (IBTX) Surges 8.7%: Is This an Indication of Further Gains?

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Business Wire

a year ago

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

10 Best Debt Free Penny Stocks To Buy Now

Insider Monkey

a year ago

10 Best Debt Free Penny Stocks To Buy Now

PureCycle Appoints Jeff Fieler as Interim CFO

ACCESSWIRE

a year ago

PureCycle Appoints Jeff Fieler as Interim CFO

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Zacks

a year ago

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Zacks

a year ago

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

Zacks

a year ago

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

ACCESSWIRE

a year ago

Monogram Orthopaedics to Host Robotic Product Demo Live Stream on Thursday, December 14, 2023 at 11:00 a.m. Eastern Time

L.B. Foster to Present at Sidoti and Singular Conferences; Updated Corporate Investor Presentation to be Posted Online

GlobeNewswire

a year ago

L.B. Foster to Present at Sidoti and Singular Conferences; Updated Corporate Investor Presentation to be Posted Online

ACCESSWIRE

a year ago

Monogram Orthopaedics Delivers First Surgical Robot

PR Newswire

a year ago

Cango Inc. Reports Third Quarter 2023 Unaudited Financial Results

Remembering Board Member Chris Stratton: A Tribute to His Legacy and Contributions

Business Wire

a year ago

Remembering Board Member Chris Stratton: A Tribute to His Legacy and Contributions

Cango Inc. to Report Third Quarter 2023 Financial Results on November 27, 2023 Eastern Time

PR Newswire

a year ago

Cango Inc. to Report Third Quarter 2023 Financial Results on November 27, 2023 Eastern Time

3 Oil Stocks That Could Heat Up This Winter

InvestorPlace

a year ago

3 Oil Stocks That Could Heat Up This Winter

Caledonia Mining Corporation Plc Chief Operating Officer to step down

GlobeNewswire

a year ago

Caledonia Mining Corporation Plc Chief Operating Officer to step down

Is Sify Technologies Limited (NASDAQ:SIFY) Potentially Undervalued?

Simply Wall St.

a year ago

Is Sify Technologies Limited (NASDAQ:SIFY) Potentially Undervalued?

Purple Innovation, Inc. (NASDAQ:PRPL) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Purple Innovation, Inc. (NASDAQ:PRPL) Q3 2023 Earnings Call Transcript

Everspin Technologies, Inc.'s (NASDAQ:MRAM) largest shareholders are retail investors with 42% ownership, institutions own 31%

Simply Wall St.

a year ago

Everspin Technologies, Inc.'s (NASDAQ:MRAM) largest shareholders are retail investors with 42% ownership, institutions own 31%

Associated Press Finance

a year ago

Protalix: Q3 Earnings Snapshot

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

PR Newswire

a year ago

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Heritage Insurance Holdings, Inc. (NYSE:HRTG) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Heritage Insurance Holdings, Inc. (NYSE:HRTG) Q3 2023 Earnings Call Transcript

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses

Simply Wall St.

a year ago

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses

Share on Social Networks: